<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="130979">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01724177</url>
  </required_header>
  <id_info>
    <org_study_id>CC-5013-ATLL-002</org_study_id>
    <nct_id>NCT01724177</nct_id>
  </id_info>
  <brief_title>A Phase 2 Study of Lenalidomide in Patients With Relapsed or Recurrent Adult T-cell Leukemia-lymphoma</brief_title>
  <official_title>A Phase 2, Multicenter, Single-arm, Open-label Study to Evaluate the Safety and Efficacy of Lenalidomide in Patients With Relapsed or Recurrent Adult T-cell Leukemia-lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Celgene Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Celgene Corporation</source>
  <oversight_info>
    <authority>Japan: Pharmaceuticals and Medical Devices Agency</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the efficacy of lenalidomide in patients with ATL who have previously received
      chemotherapy for ATL.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2012</start_date>
  <completion_date type="Anticipated">December 2015</completion_date>
  <primary_completion_date type="Anticipated">December 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Overall Response Rate</measure>
    <time_frame>Up to 3 years</time_frame>
    <safety_issue>No</safety_issue>
    <description>The primary endpoint is the overall response rate (Complete Response + Complete Response unconfirmed + Partial Response).  The response to lenalidomide will be evaluated according to the criteria proposed at the International Consensus Meeting</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival</measure>
    <time_frame>Up to 3 years</time_frame>
    <safety_issue>No</safety_issue>
    <description>Time To Progression calculated as the time from the start of study treatment to the first documented progression.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to progression</measure>
    <time_frame>Up to 3 years</time_frame>
    <safety_issue>No</safety_issue>
    <description>Progression Free Survival calculated as the time from the start of study treatment to the first documented progression or death due to any cause, whichever occurs first.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>Up to 3 years</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Number of patients with adverse events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response</measure>
    <time_frame>Up to 3 years</time_frame>
    <safety_issue>No</safety_issue>
    <description>The response duration in patients with objective responses will be measured from the date of the first Complete Response or Complete Response unconfirmed or Partial Response to the first date of Relapsed Disease or Progressive Disease.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tumor Control Rate</measure>
    <time_frame>Up to 3 years</time_frame>
    <safety_issue>No</safety_issue>
    <description>The disease control ratio (Stable Disease or Partial Response or Complete Response unconfirmed or Complete Response)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>Up to 3 years</time_frame>
    <safety_issue>No</safety_issue>
    <description>Overall Survival calculated as the time from the start of study treatment to the death due to any cause</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">25</enrollment>
  <condition>Adult T-Cell Leukemia-Lymphoma</condition>
  <arm_group>
    <arm_group_label>Lenalidomide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lenalidomide</intervention_name>
    <description>25 mg of Lenalidomide administered orally once daily</description>
    <arm_group_label>Lenalidomide</arm_group_label>
    <other_name>Revlimid</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Must understand and voluntarily sign the informed consent

          -  Aged 20 years or older (at the time of signing the informed consent)

          -  Have a documented diagnosis of either: acute-, lymphoma-, or unfavorable chronic-type
             adult T-cell leukemia-lymphoma

          -  Have received ≥1 prior anti-adult T-cell leukemia-lymphoma therapy, have achieved
             stable disease or better on their immediately prior therapy and have relapsed or
             progressed at the time of obtaining signed informed consent

          -  Subjects for whom at least 1 measurable lesion (Measurable lesion of computed
             tomography scan, peripheral blood or skin lesion) is confirmed in the lesion
             assessment before registration

          -  Have an Eastern Cooperative Oncology Group performance status of 0 to 2 at
             registration

          -  Must be able to adhere to the study visit schedule and other protocol requirements

          -  Must agree to comply to Lenalidomide Pregnancy Prevention Risk Management Plan

        Exclusion Criteria:

          -  Have a history of central nervous system involvement or present with central nervous
             system symptoms, and are diagnosed with central nervous system lymphoma by
             cerebrospinal fluid cytology examination, head computed tomography scan or brain
             magnetic resonance imaging during the screening

          -  Are pregnant or lactating

          -  Any condition including the presence of laboratory abnormalities, which places the
             subject at unacceptable risk if he/she were to participate in the study.  Examples of
             such medical condition are, but are not limited to, as follows:

               -  Uncontrolled diabetes mellitus as defined by the investigator or
                  sub-investigator

               -  Chronic congestive heart failure (New York Heart Association Class III or IV)

               -  Unstable angina pectoris, angioplasty, stenting, or myocardial infarction
                  (within 6 months before starting the study drug)

               -  Clinically significant cardiac arrhythmia that is symptomatic or requires
                  treatment, or asymptomatic sustained ventricular tachycardia (subjects with
                  controlled atrial fibrillation that is asymptomatic are eligible for this study)

               -  Major surgery within 28 days of the start of study treatment

          -  Exhibit grade 4 neurological disorders

          -  Patients who are at a high risk for a thromboembolic event and are not willing to
             take venous thromboembolic prophylaxis.

          -  Develop active tuberculous disease, herpes simplex, systemic mycosis, or other active
             infections requiring systemic administration of antibiotics, antiviral agents, or
             antifungal drugs

          -  Known human immunodeficiency virus positivity

          -  Have hepatitis B surface antigen-positive, or hepatitis C virus anti-body positive.
             In case hepatitis B core antibody and/or hepatitis B surface antibody is positive
             even if hepatitis B surface antigen-negative, a hepatitis B virus deoxyribonucleic
             acid test should be performed and if positive the subject will be excluded

          -  Any significant medical condition, laboratory abnormality, or psychiatric illness
             that would prevent the subject from participating in the study

          -  Have a history of allogenic stem cell transplantation

          -  Have received autologous stem cell transplantation within 12 weeks (84 days) of the
             start of study treatment

          -  Have previously used lenalidomide

          -  Have a history of desquamating (blistering) rash while taking thalidomide

          -  Have received any investigational drugs (unapproved drugs in Japan) within 4 weeks
             (28 days) of the start of study medication

          -  Have received any antibody agents within 12 weeks (84 days) of the start of study
             medication

          -  Have received chemotherapeutic agents or immunomodulatory drugs for the treatment of
             adult T-cell leukemia-lymphoma within 4 weeks (28 days) of the start of study
             treatment

          -  Have received radiotherapy within 4 weeks (28 days) of the start of study treatment

          -  Have a history or complication of another malignant tumor other than adult T-cell
             leukemia-lymphoma and the following malignant tumors, unless the patients have been
             free of the disease for 5 years or longer

               -  Basal cell carcinoma of the skin

               -  Squamous cell carcinoma of the skin

               -  Cervical carcinoma in situ

               -  Carcinoma in situ of the breast

               -  An incidental histological finding of prostate carcinoma (TNM stage T1a or T1b)

               -  Early-stage gastric cancer treated with endoscopic mucosal resection or
                  endoscopic submucosal dissection

          -  Have had any of the following abnormal measurements at screening performed within 1
             week (7 days) prior to the registration;

               -  Neutrophil count: &lt; 1,200/µL

               -  Platelet count: &lt; 75,000/µL

               -  Serum aspartate aminotransferase/glutamyl oxaloacetic transaminase or alanine
                  aminotransferase/glutamyl pyruvic transaminase: &gt; 3 times the upper limit of
                  normal

               -  Bilirubin level: &gt; 1.5 times the upper limit of normal

               -  Creatinine clearance: &lt; 60 mL/min

          -  Any condition that confounds the ability to interpret data from the study.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Toru Sasaki</last_name>
    <role>Study Director</role>
    <affiliation>Celgene K.K.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Tetsuhiro Shiota</last_name>
    <phone>+81-3-3580-5125</phone>
    <email>tshiota@celgene.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Nagoya Daini Red Cross Hospital</name>
      <address>
        <city>Nagoya</city>
        <state>Aichi</state>
        <zip>466-8650</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Nagoya City University Hospital</name>
      <address>
        <city>Nagoya</city>
        <state>Aichi</state>
        <zip>467-8602</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>National Cancer Center Hospital East</name>
      <address>
        <city>Kashiwa</city>
        <state>Chiba</state>
        <zip>277-8577</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ehime University Hospital</name>
      <address>
        <city>Toon</city>
        <state>Ehime</state>
        <zip>791-0295</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Iwate Medical University Hospital</name>
      <address>
        <city>Morioka</city>
        <state>Iwate</state>
        <zip>020-8505</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Tokai University Hospital</name>
      <address>
        <city>Isehara</city>
        <state>Kanagawa</state>
        <zip>259-1193</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Tohoku University Hospital</name>
      <address>
        <city>Sendai</city>
        <state>Miyagi</state>
        <zip>980-8574</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Sasebo City General Hospital</name>
      <address>
        <city>Sasebo</city>
        <state>Nagasaki</state>
        <zip>857-8511</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Heart Life Hospital</name>
      <address>
        <city>Nakagami</city>
        <state>Okinawa</state>
        <zip>901-2492</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Shimane University Hospital</name>
      <address>
        <city>Izumo</city>
        <state>Shimane</state>
        <zip>693-8501</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>National Hospital Organization Kyushu Cancer Center</name>
      <address>
        <city>Fukuoka</city>
        <zip>811-1395</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Kyushu University Hospital</name>
      <address>
        <city>Fukuoka</city>
        <zip>812-8582</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Kagoshima University Medical and Dental Hospital</name>
      <address>
        <city>Kagoshima</city>
        <zip>890-8520</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Imamura Bunin Hospital</name>
      <address>
        <city>Kagoshima</city>
        <zip>890-0064</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>National Hospital Organization Kagoshima Medical Center</name>
      <address>
        <city>Kagoshima</city>
        <zip>892-0853</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Kumamoto University Hospital</name>
      <address>
        <city>Kumamoto</city>
        <zip>860-8556</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>The Japanese Red Cross Nagasaki Genbaku Hospital</name>
      <address>
        <city>Nagasaki</city>
        <zip>852-8511</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Nagasaki University Hospital</name>
      <address>
        <city>Nagasaki</city>
        <zip>852-8501</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Oita Prefectual Hospital</name>
      <address>
        <city>Oita</city>
        <zip>870-8511</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>National Cancer Center Hospital</name>
      <address>
        <city>Tokyo</city>
        <zip>104-0045</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>March 2014</verification_date>
  <lastchanged_date>March 28, 2014</lastchanged_date>
  <firstreceived_date>November 7, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Lenalidomide</keyword>
  <keyword>ATL</keyword>
  <keyword>ATLL</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>No</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, T-Cell</mesh_term>
    <mesh_term>Leukemia-Lymphoma, Adult T-Cell</mesh_term>
    <mesh_term>Lymphoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Lenalidomide</mesh_term>
    <mesh_term>Thalidomide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
